Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About SuppreMol

SuppreMol is a privately held biopharmaceutical company developing therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in Phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's pipeline also includes two antibody development programs utilizing the inhibitory effect of FcgRIIB suitable for alternative treatment strategies and indications.

Headquarters Location

Am Klopferspitz 19a

Munich, D-82152,


+49 (0)89 30 90 50 680

Missing: SuppreMol's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SuppreMol's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SuppreMol

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SuppreMol is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SuppreMol Patents

SuppreMol has filed 10 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Autoimmune diseases, Immune system, Olfactory receptors, Immunology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Autoimmune diseases, Immune system, Olfactory receptors, Immunology



Latest SuppreMol News

SuppreMol GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14092017 Prices from USD $250

Oct 9, 2017

Summary SuppreMol GmbH SuppreMol, a subsidiary of Baxalta Inc, is a biopharmaceutical company that develops therapeutics in the areas of autoimmune , chronic inflammatory diseases, and allergies . The company's lead drug candidate is extensively profiled in invitro, exvivo and invivo experiments. Its antibody is used to restrict cellular activation signals mediated by the B cell receptor. SuppreMol also works on antiFc?RIIb antibodies, which can be useful for the treatment of autoimmune diseasesand allergic reactions . The company conducts research and development to develop new drugs. SuppreMol is headquartered in Munich, Germany. SuppreMol GmbH Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

SuppreMol Frequently Asked Questions (FAQ)

  • When was SuppreMol founded?

    SuppreMol was founded in 2002.

  • Where is SuppreMol's headquarters?

    SuppreMol's headquarters is located at Am Klopferspitz 19a, Munich.

  • What is SuppreMol's latest funding round?

    SuppreMol's latest funding round is Acquired.

  • How much did SuppreMol raise?

    SuppreMol raised a total of $40.43M.

  • Who are the investors of SuppreMol?

    Investors of SuppreMol include Baxter International, MIG Verwaltungs, FCP Biotech Holding, Santo Holding, BioMedPartners and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.